Immune to Cancer: The CRI Blog
-
Phase 3 Trial of Nivolumab Shows Survival Advantage in Lung Cancer
The results of a phase III trial are clear: the PD-1 checkpoint inhibitor nivolumab improves survival for…
-
Could That Steak Be Giving You Cancer?
A CRI postdoctoral fellow was part of the team investigating the relation of red meat to cancer…
-
The Marathon to End All Marathons: The Great Wall of China Marathon with Emma Saunders
With her family ravaged by cancer, Emma wanted to do something huge to help conquer the disease….
-
CRI’s 2014 Blog in Review: Top 10
We reflect on our favorite blog posts of 2014, including FDA approvals, editorials, conference coverage, history, awards,…
-
Smart Giving this Holiday Season
Before you make your donation to any organization, take some time to learn about their charity ratings.
-
New Cancer Immunotherapy Opdivo Approved by FDA
Just hours ago, the FDA approved Bristol-Myers Squibb's PD-1 drug for melanoma.
-
Faces of CRI: Introducing the People Who Make It Possible!
This holiday season, meet five Cancer Research Institute (CRI) staff members who want you to know why…
-
Breaking Through: 2014 Annual Report Highlights
Discover why this past year was one of many breakthroughs for the Cancer Research Institute with our…
-
FDA Approves New Immunotherapy for Leukemia
Amgen’s Blincyto was approved by the FDA, making it the first approved bispecific T cell engaging (BiTE)…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.